SCHEMBL3637614

SCHEMBL3637614

CCCC(=O)c1ccc(NCc2ccc(-c3cccc(C(F)(F)F)c3)o2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FRK P42685 1/20 0.48
▸ CAMK2B Q13554 1/20 0.48
▸ CAMK2G Q13555 1/20 0.48
▸ CAMK2D Q13557 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ MAPT P10636 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ CACNA1G O43497 1/20 0.46
▸ CACNA1B Q00975 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.45
▸ PRMT1 Q99873 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640783 0.84 L3MBTL1 (0.59) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL3635886 0.78 THRB (0.52) FRKCAMK2BCAMK2GCAMK2DALDH1A1
SCHEMBL3634755 0.77 FRK (0.55) FRKCAMK2BCAMK2GCAMK2DALDH1A1
SCHEMBL3632562 0.75 CA1 (0.47) FRKCAMK2BCAMK2GCAMK2DALDH1A1
SCHEMBL3640718 0.74 MAPT (0.45) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL3639002 0.74 ALDH1A1 (0.46) FRKCAMK2BCAMK2GCAMK2DALDH1A1
SCHEMBL12519881 0.72 PRMT1 (0.57) ALDH1A1MEN1KMT2ACACNA1GCACNA1B
SCHEMBL3636785 0.71 FRK (0.61) FRKCAMK2BCAMK2GCAMK2DFFAR1
SCHEMBL2157913 0.71 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL12357238 0.71 KDM4E (0.49) ALDH1A1MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 — — US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 — — EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 — — WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 FRK 2372/4885CAMK2B 250/4885CAMK2G 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback